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Abstract
Purpose To evaluate and understand the genetic and epigenetic basis of bulimia nervosa/bulimia spectrum disorder and 
comorbid borderline personality disorder (BN/BSD-BPD).
Methods The present systematic review was conducted in accordance to PRISMA guidelines. Advanced systematic searches 
of Medline, EMBASE, PsychINFO, Web of Science, Scopus, CINHAL plus, and the Cochrane Library were conducted using 
the search terms ‘bulimia nervosa’, ‘bulimia spectrum disorder’, ‘borderline personality disorder’, ‘genes’, and ‘genetics’. 
The search strategy garnered seven studies for inclusion in the present review.
Results Women with BN/BSD-BPD had significantly lower serotonin and monoamine oxidise activity compared to women 
with BN/BSD or healthy controls (HC). As well, women with BN/BSD-BPD displayed elevated methylation of the dopamine 
receptor gene promoter, brain-derived neurotrophic factor, and changes in the methylation of the glucocorticoid receptor 
gene promoter (NR3C1) compared to women with BN/BSD and HC. The results also demonstrated that rates of childhood 
sexual abuse and childhood physical abuse are higher in those with BN/BSD-BPD than those with BN/BSD and HC, and 
that these types of abuse are often correlated with the methylation differences seen in BN/BSD-BPD women.
Conclusion Due to the differences observed between individuals with BN/BSD-BPD and those with BN/BSD and HC a 
genetic/epigenetic aetiological model of BN/BSD-BPD was developed and is proposed in this review. This evidence-based 
model visually illustrates the current state of the field and draws attention to the need for subsequent research.
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Introduction
Bulimia nervosa, bulimia spectrum disorder, 
and borderline personality disorder
What is bulimia nervosa and bulimia spectrum disorder?
Bulimia nervosa (BN) is a multifaceted eating disorder 
(ED) characterized by an overvaluation of body shape and/
or weight on self-image, coupled with recurrent episodes 
of binge eating and compensatory behaviours in attempts 
to lose weight [1]. The Diagnostic and Statistical Manual 
of Mental Disorders, fifth edition (DSM-5) includes both 
BN and bulimia spectrum disorder (BSD), however, BSD 
is referred to as “bulimia nervosa of low frequency and/
or limited duration” [2]. Many studies include both BN 
and BSD individuals to represent the bulimic population 
as these groups do not differ considerably on most clinical 
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indices [3]. The thoughts and behaviours of those with BN 
and BSD are the same; the only difference between the two 
groups is the frequency of which the individual engages in 
the bulimic behaviours. Specifically, the DSM-5 states that 
BN individuals engage in bingeing and compensatory behav-
iours at least once a week (on average) for a minimum of 
3 months, whereas BSD individuals experience binge eating 
episodes and inappropriate compensatory behaviours less 
than once a week on average and/or for less than 3 months 
[2]. Thus, BSD can be defined as BN with limited frequency 
of compensatory behaviours. For simplicity and continuity, 
the present review refers to both these groups as BN/BSD.
What is borderline personality disorder?
Borderline personality disorder (BPD) is an intricate disor-
der characterized by affect instability, poor impulse control, 
impaired interpersonal relationships, and unstable self-
image [4]. Complex comorbidity is a hallmark of BPD, and 
affected individuals demonstrate a greater likelihood of pre-
senting with three or more psychiatric diagnoses compared 
to those without BPD.
Comorbidity of bulimia nervosa/bulimia spectrum 
disorders and borderline personality disorder
BPD presents alongside BN/BSD in approximately 35% 
of cases [5]. As these conditions are often comorbid they 
share many of the same risk factors, phenotypes, and behav-
ioural traits including: attachment disturbances [6], adverse 
childhood experiences [7], non-suicidal self-injury [8], 
interpersonal difficulties [4, 9], and comorbid maladaptive 
mood and impulse regulation behaviours [10, 11]. In lieu 
of the large degree to which BPD interferes with interper-
sonal functioning, sense of self, and quality of life, it can 
be hypothesized that the 35% of those with BN/BSD and 
comorbid BPD (BN/BSD-BPD) face unique challenges. As 
well, it is believed that BN/BSD and BPD behaviour interact 
to hinder treatment as irregular eating patterns seem to inten-
sify dysregulated moods, impulsivity, and other maladaptive 
symptomology, which, in turn, perpetuate the disordered eat-
ing behaviour as a coping strategy [12]. Little research has 
focused on the 35% of BN/BSD sufferers with comorbid 
BPD. As this condition is understudied and sufferers are 
greatly impacted by the disorder, research focused on under-
standing the genetic and epigenetic changes pertinent to BN/
BSD-BPD will likely benefit the care given to these indi-
viduals, increase sufferer’s quality of life, and lead to better 
recovery outcomes for this population as efforts can be made 
to specifically target the individual’s biological changes and 
associated behaviours and symptoms.
Biological variables associated with both bulimia 
nervosa/bulimia spectrum disorder and borderline 
personality disorder
In addition to shared behavioural traits, individuals with 
BN/BSD-BPD are also similar on many genetic and epi-
genetic variables. This will be discussed below and their 
prevalence will be investigated in the subsequent research. 
It is important to note that genome-wide association stud-
ies reveal connections between the genes relevant to the 
current research and other psychopathologies; therefore, 
they are not unique to BN/BSD and BDP symptomology 
[13]. This does not negate the importance of the genetics/
epigenetics relevant to BN/BSD-BPD, it is simply impor-
tant to be aware of the boarder context of the research. 
Furthermore, it is important to note that it is not known 
for certain whether these genetic/epigenetic changes are 
premorbid or if they arise due to BN/BSD-BPD behav-
iours. However, understanding the genetic variants associ-
ated with the behaviours and symptoms of BN/BSD-BPD 
may help explain an individual’s response to treatment 
and could help improve treatment outcomes in this popu-
lation [14]. Previous research has found that those with 
BN/BSD-BPD experience more severe psychopathology, 
reduced global psychosocial functioning, increased inter-
personal difficulties, and more frequent hospitalizations 
compared to BN/BSD individuals without comorbid BPD 
[15]. Furthermore, psychosocial treatment is thought to 
be less effective in individuals with BN/BSD-BPD com-
pared to those with BN/BSD [16], and BN/BSD-BPD is 
associated with an increased risk of negative long-term 
outcomes compared to BN/BSD [17]. Understanding the 
genetic/epigenetic characteristics of BN/BSD-BPD may 
explain this observed variance in treatment response and 
could be used to further refine treatment for the individual.
Serotonin
It is widely established that central serotonin and eating 
behavior interact. Both human and animal studies have 
demonstrated an inverse relationship between serotonin neu-
rotransmitter activity and food consumption [18]. Further, 
when single photon emission computer tomography was 
employed to compare serotonin transporter levels in women 
with BN/BSD and age-matched healthy controls a significant 
negative correlation between serotonin transporter levels and 
illness duration in the BN/BSD population was observed 
(p = 0.042, r = − 0.65), indicating that those with BN/BSD 
have less serotonin transporter availability than healthy 
counterparts [19]. Taken together this suggests decreased 
serotonin activity corresponds with BN/BSD.
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The serotonin system has also been implicated in mood 
regulation, social behaviour, and impulsivity—all char-
acteristics of BPD [20]. Other studies have implemented 
central serotonin in BPD, particularly in relation to chronic 
feelings of emptiness [21], impulsiveness [22], suicidality, 
and emotional dysregulation [23]. Thus, decreased central 
serotonin has been implicated in both BN/BSD and BPD.
The 5-hydroxytryptamine [5-HT] transporter polymor-
phism (5-HTTLPR) has been correlated with low transcrip-
tion of the serotonin transporter protein, increased depres-
sion after tryptophan depletion (the precursor to serotonin), 
and clinical manifestations of both BN/BSD and BPD (dis-
cussed above) [24]. Polymorphisms of this transporter gene 
in relation to BN/BSD and BPD will be investigated further 
in the present systematic review.
Monoamine oxidase
Monoamine oxidase (MAO) is an enzyme involved in 
removing the neurotransmitters serotonin, dopamine, nor-
epinephrine, and epinephrine from the brain [25]. Many 
studies have used platelet MAO activity as an index of 
these neurotransmitters, and have used blood levels of these 
neurotransmitters as a proxy for MAO activity in individu-
als with BN/BSD and BPD. Lower MAO activity is often 
observed in individuals with BN/BSD compared to healthy 
controls [26–28], however, decreased MAO activity is also 
sometimes seen in AN-R patients and, therefore, cannot be 
exclusively attributed to BN/BSD [28].
Low MAO activity has also been correlated to BPD 
symptoms including impulsiveness, affect dysregulation, 
sensation seeking, substance abuse, and suicide ideation and 
attempts [29, 30]. As well, decreased platelet MAO activ-
ity has been implicated in cluster B personality disorders, 
including BPD [31]. As low MAO activity has been impli-
cated in both BN/BSD and BPD, this review will examine 
its potential role in BN/BSD-BPD.
Epigenetics
Epigenetic changes occur when a hereditary susceptibility 
is activated because of environmental pressures [32]. One 
common epigenetic mechanism is DNA methylation. DNA 
methylation occurs when methyl groups are added to the 
cytosine of CpG islands (frequently found in the regulatory 
region of most genes) and leads to reduced DNA accessi-
bility, decreased transcriptional activity, and inhibition of 
gene expression [33, 34]. DNA methylation is not the only 
epigenetic modification that occurs in humans, other com-
mon epigenetic mechanisms include histone modification 
and noncoding RNA action [35]. The details of these epi-
genetic regulation mechanisms are beyond the scope of the 
present systematic review as all of the epigenetic studies 
included in the review only report epigenetic regulation 
resulting from DNA methylation; however, it is important 
to be aware that DNA methylation is not the sole epigenetic 
change that occurs. Childhood abuse is frequently cited as 
the “environmental pressure” that is associated with epi-
genetic effects correlated with BN/BSD and BPD sympto-
mology and behaviour [32, 33]. Many other factors beyond 
abuse affect epigenetic regulation, some of these factors 
include: environmental pollutants, nutritional factors, and 
maternal behaviour (e.g., nursing behaviour or depression) 
[36]. Thus, although the epigenetic studies included in this 
review specifically examine the role of childhood abuse on 
the observed epigenetic changes, other factors also likely 
impact the epigenetic patterns observed. Furthermore, when 
interpreting the results presented in this review it should be 
noted that variability can exist between methylation levels of 
CpG sites within the same CpG island and this in turn may 
elicit differential gene expression [37]. Overall, epigenetic 
effects are complex and it is nearly impossible to attribute a 
change to a specific environmental factor, however, correla-
tion between environmental factor (e.g., abuse) and epige-
netic changes (e.g., DNA methylation) can be established. 
The present review will examine methylation of the gluco-
corticoid receptor promoter gene (NR3C1), brain derived 
neurotrophic factor (BDFN), and the dopamine receptor 
gene promoter (DRD2) in women with BN/BSD-BPD.
The glucocorticoid receptor is central to modulating 
individuals stress reactivity, and anomalies in this system 
have been associated with BN/BSD and BPD. Studies have 
associated BN/BSD with reduced inhibition of the hypo-
thalamic–pituitary–adrenal stress response (a glucocorticoid 
receptor modulated response) [32]. As well, hyper-methyla-
tion of neuro-regulatory genes, including NR3C1, has been 
correlated with psychopathologies including suicidality, 
BPD, and BN/BSD [38]. Furthermore, childhood abuse has 
been associated with increased methylation of various gluco-
corticoid receptor gene exon-1 promoter variants in human 
studies [39]. As such, childhood abuse, methylation of the 
NR3C1, and BN/BSD-BPD may be correlated; this will be 
examined further in this review.
BDFN has been implicated in the regulation of food 
intake and energy homeostasis in the general population, 
and is observed to be reduced in AN and BN/BSD popula-
tions [33]. Studies have found that methylation of the BDFN 
gene differs between BPD and healthy control populations, 
with increased methylation seen in the BPD population [38]. 
As well, early developmental stress has been implicated in 
the hyper-methylation of the BDFN gene [40], again creat-
ing a potential connection between childhood abuse, BN/
BSD, and BPD.
Finally, studies have found associations between the 
DRD2 Taq1 polymorphism and symptoms related to both 
BN/BSD and BPD (e.g., binge eating, emotional eating, 
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food cravings, impulsivity, and novelty seeking) [41]. As 
with the previous two genes, childhood abuse is thought 
to be associated with methylation of the DRD2 gene [42], 
again indicating a potential link between childhood abuse, 
BN/BSD, and BPD.
The scope of the current paper
The relationship between BN/BSD and comorbid BPD is 
complex and remains to be fully understood. The present 
paper will use current literature to explore the ways in 
which BN/BSD-BPD may be influenced by genetic and 
epigenetic factors. This paper will clearly outline these 
developments and will provide a coherent summary of the 
current state of the field. As well, a genetic/epigenetic aeti-
ological model of BN/BSD-BPD will be proposed which 
summarizes the current findings and illustrates the need 
for future research.
Methods
Search strategy
An extensive electronic search was conducted to ascertain 
relevant papers for the current systematic review from the 
following databases: Medline, EMBASE, PsychINFO, 
Web of Science, Scopus, CINHAL plus, and the Cochrane 
Library (Table 1). Advanced searches were completed in 
all the aforementioned databases using the search terms 
‘bulimia nervosa’, ‘bulimia’, ‘borderline personality dis-
order’, ‘borderline adj4 personality disorder’, ‘genes’, and 
‘genetics’. The search was limited to articles containing 
one relevant term to each of the three categories of the 
search [1] bulimia nervosa, [2] borderline personality 
disorder, and [3] genetics (refer to online appendix 1 for 
a summary of the search strategy). No restrictions were 
placed on the year of publication, or the language.
Selection of studies
The search strategy garnered a total of 1066 papers. After 
deduplication 1006 remained. Reviews, book sections, 
commentaries, theses and dissertations were then removed 
(n = 188). The articles were then reviewed to ensure they 
encompassed all three aspects of the inclusion criteria 
(bulimia nervosa/bulimia spectrum disorder, borderline 
personality disorder, and a genetic or epigenetic variable). 
This resulted in seven relevant articles to be included in the 
present review (Fig. 1).
Procedure
To investigate the role of genetics and epigenetics in BN/
BSD with comorbid BPD (BN/BSD-BPD) the articles iden-
tified through the search strategy were reviewed and grouped 
by topic. The results from each topic were summarized and 
discrepancies between studies were identified. The limita-
tions of the studies were addressed and areas that require 
further research were outlined. Finally, the implications of 
better understating the ways in which genetics/epigenetics 
are involved in BN/BSD-BPD were discussed.
Table 1  The number of articles 
gathered using the search 
strategy in November 2018, and 
the corresponding database
Database Number 
of articles
CINAHL plus 4
Cochrane Library 5
EMBASE 24
Medline 10
PsychINFO 19
Scopus 983
Web of Science 21
Total 1066
Total number of
results generated
from search strategy
(n=1066)
Duplicates removed
(n=60)
Articles remaining
(n=1006)
Book sections, books,
dissertations, theses,
and reviews removed
(n=208)
Articles remaining
(n=798)
Irrelevant articles
removed (n=791)
Articles remaining
(n=7)
Fig. 1  Search strategy process
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Results
Overview of studies
Seven studies fulfilled the inclusion criteria and were 
included in the review. These seven studies can be roughly 
classified into three groups: (1) polymorphisms of the ser-
otonin transporter promoter (5-HTTLPR) gene (n = 2) [20, 
24], (2) gene methylation of: the dopamine gene receptor 
(dopamine D2 receptor (DRD2) promoter (n = 1) [41], the 
glucocorticoid receptor gene (NR3C1) promoter) (n = 1) 
[32] and brain-derived neurotrophic factor (BDNF) (n = 1) 
[33], and (3) monoamine oxidize (MAO) activity (n = 2) 
[28, 43].
Study characteristics
Most of the studies were conducted in Canada (n = 5), and 
the remaining studies were conducted in Spain (n = 2). 
Each study included in this review obtained informed con-
sent from participants and were of cross-sectional design. 
The majority of the studies were independent from each 
other and recruited participants through ED services and 
advertisements in newspapers and university bulletins 
(n = 5), however, two studies obtained their samples from 
the same pre-existing database developed for a large-scale, 
institutional ethics board approved study.
The sample sizes of the studies included in the sys-
tematic review range from 59 to 308 (mean n = 126.67 
SD = ± 90.31), with a total of 760 participants (note: this 
reflects the fact that two studies used the same sample of 
participants). All participants in the studies were female. 
Most of the studies included an ED group(s) and a healthy 
control group (n = 5), but two just involved individuals 
with an ED. Of the total sample size, 568 individuals were 
diagnosed with an ED and the remaining 192 participants 
were HC without an ED. ED diagnoses were based on 
the criteria outlined in the DSM-IV in six of the studies, 
however, the most recent study, conducted in 2014, used 
the DSM-5 criteria. Of the 568 who fit the criteria for an 
ED 506 were diagnosed with BN or BSD (89.1%), 19 with 
binge/purge type AN (AN-BP) (3.3%), 25 with restric-
tive AN (AN-R) (4.4%) and 18 with EDNOS (3.2%). BSD 
and/or BN were frequently used in the studies included in 
the present systematic review to encompass bulimia. The 
participants were 17 years to 49 years old, with the mean 
age ranging from 20.06 years to 26.05 years across studies.
The study aims varied between the seven studies; how-
ever, they all generally examined the relationship between 
BN/BSD and BPD along with a biological variable. Two 
studies explored the effects of polymorphisms in the 
5-HTTLPR serotonin transporter promoter gene in indi-
viduals with BN/BSD-BPD; however, each study exam-
ined this relationship in the context of different additional 
variables. These variables include childhood abuse (sexual 
and physical) (n = 1) [20], impulsive behaviours (n = 2) 
[20, 24], insecure attachment (n = 1) [20], interpersonal 
difficulties (n = 1) [24], and affect instability (n = 1) [24]. 
One study also explored the 5-HTTLPR polymorphism 
in relation to the density of paroxetine-binding sites [24].
MAO activity in individuals with BN/BSD, BN/BSD-
BPD, and HC was central to two studies [28, 43]. One 
study investigated differences in psychological traits (e.g., 
impulsivity) and MAO activity, as well as interactions 
between these variables in the aforementioned groups 
[43]. The second study had a similar objective to the first. 
This study aimed to understand the relationship between 
platelet MAO activity and borderline personality traits in 
individuals with an ED [BN/BSD, AN-BP, and anorexia 
nervosa not otherwise specified (AN-NOS)] and individu-
als with BN/BSD-BPD, compared to HC [28].
Three studies focused on the methylation of particular 
genes in women with BN/BSD-BPD, BN/BSD, and HC 
and associations with childhood abuse (sexual or physical) 
[32, 33, 41]. The genes under question were: brain-derived 
neurotrophic factor (BDNF) [33], the glucocorticoid 
receptor gene promoter (NR3C1) [32], and the dopamine 
receptor gene promoter (DRD2) [41]. When interpreting 
the results, it is important to note that DNA methylation 
was measured from DNA samples obtained from blood. 
As DNA methylation is cell-specific, the methylation 
patterns reported in the studies do not necessarily reflect 
DNA methylation of these genes in the brain.
The majority of the studies (n = 5) [20, 24, 32, 33, 41] 
employed the eating disorders examination (EDE) to iden-
tify if participants and controls had an ED or not [44]. Two 
studies did not use the EDE to identify ED in participants 
[28, 43], but in both these cases the Bulimic Investiga-
tory Test Edinburgh (BITE) was commissioned [45]. Sup-
plementary ED diagnostic tests were undertaken in three 
studies (refer to Table 2 for a full list) [20, 24, 28].
In addition to the psychological tests, each study under-
took biological measurements to identify the genetic or 
epigenetic variable under question. To perform the meth-
ylation analyses one study employed pyrosequencing 
techniques [41], and two used Epityper methods [32, 33]. 
Other, more specific procedures were done in most stud-
ies to properly investigate methylation of promoter genes, 
MAO activity, and polymorphisms of the 5-HTTLPR pro-
moter gene (see Table 2 for more details).
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Key findings
Five of the studies compared ED groups to HC [28, 32, 33, 
41, 43], while the remaining two studies simply focused on 
an ED population [20, 24]. All seven studies focused on BN/
BSD as the ED under question. A few studies also looked 
at differences between other subtypes of EDs (n = 3), for 
example, AN-R and AN-BP [20, 24, 28]. Of the three stud-
ies that included various types of ED, one examined the 
rate at which BPD presented alongside each ED [28]. This 
study found that comorbid BPD was significantly higher 
in individuals with BN/BSD (33%), and AN-BP individu-
als (29.4%) than AN-R (12%). Additionally, covariates 
that could alter statistical significance of the findings were 
investigated in seven of the studies. These covariates were: 
frequency of binge and purge behaviour, BMI, and use of 
psychoactive medication. All seven studies found that these 
covariates did not alter the statistical significance of analy-
ses, however, two studies used an un-medicated sample [28, 
32]; therefore, the medication covariate was only relevant in 
five of the studies. Table 3 provides a summary of the studies 
included in the present review.
Two studies examined the 5-HTTLPR polymorphism in 
women with BN/BSD-BPD. Traditionally, the 5-HTTLPR 
polymorphism was categorized using a biallelic model 
which included an S (short) allele and an L (long) allele, 
which coded for low or high serotonin transporter activity, 
respectively [46]. However, more recent research argues 
for a triallelic model of the 5-HTTLPR polymorphism as 
evidence suggests there is a “low-frequency” L allele vari-
ant,  LG which functions like the low-function S allele. This 
variant is simply an L allele containing an A → G single-
nucleoid polymorphism in its sequence. Simply, the S and 
 LG alleles can be classified as “low-function” variants and 
the  LA allele can be classified as a “high-function” vari-
ant [47]. One of the studies conducted analyses using both 
the biallelic and triallelic models [20], and the other study 
used only the biallelic model [24] (see Table 4 for geno-
type allele distribution of samples). Neither study found an 
association between allelic variants and eating pathology 
(e.g., binge and purge frequency, BMI, and one found no 
association between allelic variants and body dissatisfac-
tion or eating attitudes (however, one study did not look at 
this). Both studies analysed the relationship between BPD 
Table 2  Diagnostic tests 
employed by the studies Diagnostic test No. of studies (n)
Psychological measurements
 Bulimic Investigatory Test Edinburgh (BITE) 2
 Eating Attitudes Test–26 (EAT-26) 2
 Eating Disorders Examination (EDE) 5
 Eating Disorders Inventory (EDI) 1
 Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) 3
 Structured Interview for DSM-IV Axis II Disorders (SCID-II) 3
 Diagnostic Interview Schedule, Version IV (DIS4) 2
 Dimensional Assessment for Personality Pathology (DAPP) 2
 Diagnostic Interview for Borderline Personality Disorder (DIB-R) 1
 Zanarini Rating Scale (ZAN-BPD) for severity of BPD 1
 Beck Depression Inventory (BDI) 1
 Centre for Epidemiological Studies Depression Scale (CES-D) 1
 Self-defeating personality subscale of the Millon Clinical Multiaxial Inventory (MCMI-II) 1
 Barrat Impulsiveness Scale 3
 Impulsivity Behavioural Scale-Revised (IBS-R) 1
 Childhood Trauma Interview (CTI) 4
 Clinician-Administered PTSD Scale (CAPS) 2
 Computerized go/no go discrimination test to indicate disinhibition 1
Biological measurements
 Platelet MAO activity measured by isotopic methods 1
 DNA extracted from blood and used for methylation analyzes by pyrosequencing methods 1
 Urinary 24-h excretion of noradrenalin (NE), serotonin (5-HT), and dopamine (DA) and 
their main metabolites quantified using column chromatographic methods
1
 Serum cortisol determined from a sample of fasted (12 h) blood 1
 DNA methylation assessed using the EpiTYPER platform 2
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and allele frequency and both found that those who met 
the criteria of BPD had higher frequencies of the S allele 
than their non-BPD counterparts. All the individuals with 
BPD were found to be carriers of the S allele (n = 1) [24], 
and in another study 90.5% of individuals with BPD were 
carriers of the S allele [20]. In comparison, only 50.8% of 
individuals without BPD were carriers of the S allele (n = 1) 
[20]. When the biallelic model was used in analyses, the 
S allele was associated with significantly higher instabil-
ity [t(53) = − 2.46, p < 0.02, d = 0.71] (n = 1) [24], insecure 
attachment [t(53) = − 2.43, p < 0.02, d = 0.70] (n = 1) [24], 
affect instability [t(53) = − 2.46, p < 0.02, d = 0.71] (n = 1) 
[24], disinhibition [t(53) = − 2.23, p < 0.03, d = 2.98] (n = 1) 
[24], and a significantly lower density of  [3H-] paroxetine-
binding sites [t(53) = 2.38, p < 0.03, d = 0.64] (n = 1) [24]. 
When relationships were analysed using the triallelic model 
no significant effects were obtained in relation to stimulus 
seeking and insecure attachment, but the results pointed in 
the same direction as the biallelic model (n = 1) [20].
Two studies examined MAO in relation to groups of 
women with BN/BSD-BPD, BN/BSD, and HC [28, 43]. 
One focused on platelet MAO activity measured through 
isotopic measures [28], whereas the other focused on clinical 
variables that reflect MAO activity determined through 24-h 
urinary excretion [43]. These clinical variables included: 
serotonin, dopamine, norepinephrine, as well as their metab-
olites (5-hydroxyindole-acetic acid, homovanillic acid, and 
3-methoxy-4-hydroxyphenylglycol, respectively).
The study that examined platelet MAO found that ED 
patients had significantly lower MAO activity than HC 
(p < 0.01, d = 0.76) [28]. As well, MAO activity was mark-
edly lower in BN/BSD and AN-BP patients with comorbid 
BPD than ED counterparts without BPD (t = 4.7, p < 0.05, 
d = 0.63). Furthermore, this study observed that platelet 
MAO activity was inversely related to the severity of BN/
BSD symptoms (r = − 0.31, p < 0.05) as well as the severity 
of BPD (r = −0.42, p < 0.01).
Clinical variables that reflect MAO activity were signifi-
cantly lower in BN/BSD patients than HC (24-h excretion 
of serotonin [RoM = 0.7 (0.5–0.9), p < 0.01]; 24-h excretion 
of dopamine [RoM = 0.8 (0.7–0.1), p < 0.04] [43]. Further-
more, MAO activity of BN/BSD-BPD patients was signifi-
cantly lower than BN/BSD patients (borderline personal-
ity traits x dopamine excretion (95% CI − 0.85 to − 0.09, 
p < 0.02). This relationship was not significant in the HC 
group. Additionally, this study observed the cortisol sup-
pression rates in relation to BN/BSD and BPD. The findings 
parallel those previously stated, with BN/BSD patients dis-
playing a significantly lower cortisol suppression rate than 
HC [RoM = 0.9 (0.9–0.8), p < 0.002], and BN/BSD-BPD 
patients having a lower cortisol suppression rate than BN/
BSD patients (95% CI − 5.88 to − 2.93, p < 0.001).
One study focused on methylation of the dopamine 
receptor (DRD2) promoter gene located on chromo-
some 11q in women with BN/BSD-BPD [41]. It was 
observed that women with BN/BSD and HC do not differ 
in mean methylation levels of the DRD2 (mean methyla-
tion = 7.35% ± 0.67 and mean methylation = 7.11% ± 0.72, 
respectively). However, women with BN/BSD-BPD showed 
significantly higher levels of DRD2 methylation compared to 
HC (p < 0.05, d = 0.90), and slightly higher levels of DRD2 
methylation compared to women with BN/BSD (p < 0.10, 
d = 0.76).
The methylation of the glucocorticoid receptor gene pro-
moter (NR3C1) exon sites 1B, 1C, 1F, and 1H in women 
with BN/BSD-BPD, BN/BSD, and HC was explored in one 
study [32]. ANOVA analyses indicated that a significant 
group × promoter-region site interaction in the 1C region 
was observed when testing BN/BSD-BPD vs. BN/BSD vs. 
HC groups [F(34,246) = 1.75, p < 0.02]. When looking at 
methylation levels in the 1C region it was observed that the 
BN/BSD-BPD group had elevated methylation compared 
to methylation levels of HC (p < 0.03). When comparing 
methylation levels between BN/BSD and the HC groups no 
differences were observed. Methylation differences at the 1H 
region were also observed. Here, the BN/BSD-BPD group 
exhibited significantly lower methylation than the HC group 
[F(2,88) = 4.86, p < 0.01]. Once again, methylation levels in 
the BN/BSD did not differ from controls.
Finally, no significant methylation differences were 
observed between BN/BSD individuals and HC. However, 
a nonsignificant trend towards a group × promoter-region 
site interaction was observed between these two groups 
[F(17,78) = 1.54, p < 0.10]. This is consistent with previous 
findings of the hyper-methylation of some sites in the 1C 
region in the BN/BSD groups compared to the HC group.
One study examined methylation of brain-derived neu-
rotrophic factor (BDNF) in women with BN/BSD-BPD, 
Table 4  Genotype allele 
distributions of samples (% of 
sample size)
Study Biallelic model Triallelic model
S/S (low–
low) (%)
S/L (low–
high) (%)
L/L (high–
high) (%)
S/S, S/LG,  LG/LG 
(low–low) (%)
LG/LA, S/LA 
(low–high) (%)
LA/LA 
(high–
high) (%)
Steiger et al. [24] 22.0 47.5 30.5 – – –
Steiger et al. [20] 19.6 46.7 33.7 31.5 44.6 23.9
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BN/BSD, and HC [33]. Methylation patterns were exam-
ined at the BDNF promoter-region fragment, located on 
chromosome 11: 27,722,840–27,723,980. When methyla-
tion patterns were analysed between the BN/BSD and the 
HC groups significant methylation patterns were observed 
and BN/BSD individuals displayed elevated methylation 
compared to HC across various CpG regions (ERR = 1.45, 
95% CI 1.07, 1.98, p values ranging from 0.003 to 0.036). 
Similarly, when comparing methylation between individuals 
with BN/BSD-BPD to HC the BN/BSD-BPD group showed 
significantly higher methylation levels across various CpG 
sites (ERR = 2.87, 95% CI 1.57, 5.54, p values ranging from 
0.01 to 0.013).
The effects of childhood abuse (physical and sexual) 
on the relationship between BN/BSD, BPD, and a bio-
logical variable were investigated in four studies. These 
studies included the genetic and epigenetic variables: the 
5-HTTLPR polymorphism (n = 1) [20], methylation of the 
DRD2 receptor gene (n = 1) [41], methylation of NR3C1 
promoter gene (n = 1) [32], and methylation of BDNF (n = 1) 
[33].
When examining childhood abuse (physical and sexual) 
in relation to BN/BSD-BPD and the 5-HTTLPR polymor-
phism, childhood abuse had a significant effect on the rela-
tionship between BN/BSD and BPD using both the biallelic 
model and the triallelic model of the 5-HTTLPR (OR 3.27, 
95% CI 1.09–9.18, p < 0.04 and OR 2.92, 95% CI 1.02–8.37, 
p < 0.05, respectively) [20]. Interestingly, 57.1% of individu-
als with BPD had been abused in childhood and only 34.8% 
of those without BPD experienced childhood abuse.
The study that focused on methylation of the DRD2 
receptor gene in women with BN/BSD and BPD looked 
at childhood sexual abuse and childhood physical abuse 
separately [41]. This study found a group effect associated 
with childhood sexual abuse [F(2,68) = 2.687, p < 0.075], 
but not childhood physical abuse in women with BN/BSD-
BPD. Pairwise comparisons of mean methylation of the 
DRD2 receptor gene revealed significantly higher levels in 
women with BN/BSD and childhood sexual abuse compared 
to HC (p < 0.03, d = 0.84) and marginally higher methyla-
tion in women with BN/BSD and childhood sexual abuse 
compared to women with BN/BSD and no childhood sexual 
abuse (p < 0.07, d = 0.65).
The findings of the paper that looked that BN/BSD and 
BPD in relation to methylation of NR3C1 promoter were 
contrary to the findings of the previous two studies [32]. 
Here, no significant or main interaction between BN/BSD-
abused women vs. BN/BSD non-abused women vs. HC 
when an ANOVA test was run.
Finally, the study looking at BN/BSD, BPD, and BDNF 
methylation in women found that women with BN/BSD 
and childhood physical abuse displayed greater meth-
ylation than HC across CpG sites on chromosome 11: 
27,722,840–27,723,980 (p values ranging from 0.001 to 
0.017, and main effect p = 0.03) [33]. When looking at 
childhood sexual abuse it was observed that women with 
BN/BSD and childhood sexual abuse had greater percent-
age methylation than HC (ERR = 1.55, 95% CI 1.08, 2.21, 
p = 0.017).
Limitations of the studies
Here the limitations of the seven studies included in the sys-
tematic review will be discussed. Table 5 outlines the limita-
tions that pertain directly to each study. The demographics 
of the studies create some limitations. Firstly, the sample of 
each study was completely female, leading to results biased 
by gender. That being said, the prevalence of BN/BSD is 
higher in females than males with a ratio of 10:1 [48] and 
there is some evidence to suggest that females are more 
affected by BPD than males [4]. Therefore, the results will 
be specific to females with BN/BSD-BPD and could inform 
treatment and prevention in this population more effectively 
than research done on both males and females. All of the 
studies were conducted in Western countries, five in Canada 
and two in Spain. This creates a westernized prejudice in 
the conclusions and limits the degree to which the results 
can be extrapolated to diverse populations and ethnici-
ties. Furthermore, research suggests that affects epigenetic 
expression; for example, diet, lifestyle, maternal care, and 
exposure to environmental toxins are all factors that affect 
DNA methylation patterns [49]. As Canada and Spain are 
both developed countries they share many environmental 
factors that would likely be different in developing coun-
tries. This further limits the generalizability of the studies 
included in the present review as many focus on epigenetics, 
and the epigenetic changes discussed could be influenced 
by the permissive culture found in both Canada and Spain. 
Additionally, the ages of the participants ranged from 17 to 
49 years old, further narrowing the specificity and relevance 
of the findings.
Each study had a small sample size (n = 59 to n = 308, 
mean n = 126.66 SD = ± 90.31), which hinders the conclu-
siveness of results through decreasing the confidence inter-
val of the study, limiting the power of the study, and increas-
ing the margins of error. This could prevent the existence of 
effect to be detected and leads researchers to question the 
clinical significance of the results. In some cases, the small 
sample size prevented researchers from analysing relation-
ships of interest (see Table 5).
It is important to note that the seven studies that met the 
inclusion were all candidate gene studies. Although these 
studies do provide valuable information about the gene in 
question, they do not explain how the gene may influence 
others, nor do they provide a comprehensive understand-
ing the genetic complexities of BN/BSD-BDP. As such, 
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when interpreting the results from the present systematic 
review it must be noted that these genes are only a very small 
piece of the genetic/epigenetic aetiology of BN/BSD-BPD. 
Much more research is needed to more fully understand the 
genetic/epigenetic complexities of BN/BSD-BPD, including 
identifying additional genetic/epigenetic variables at play 
and determining the ways in which the genetics/epigenetics 
discussed in the present review influence other genes.
BPD and BN/BSD often present alongside many other 
psychopathologies (e.g., major depressive disorder, major 
affective disorder, and anxiety disorder) but none of the 
studies controlled for this potential covariate. Additionally, 
it would be impossible to control for all confounding vari-
ables, so many were left unaccounted for (e.g., nutrition and 
lifestyle).
It is also important to note that shared genetics/epigenetic 
variables as well as behavioural traits are observed in BN/
BSD-BPD are not exclusive to this condition and are also 
observed in other psychiatric conditions. However, without 
more robust research regarding the genetics/epigenetic of 
psychological disorders it is difficult to fully understand the 
scope of influence the genetic/epigenetic variables exam-
ined in this study have on BN/BSD-BPD compared to other 
psychological conditions. As well, in relation to the genetic 
aspect of the studies, no “neutral” control genes could be 
included as they often do not exist. Therefore, it is impos-
sible to be certain that the effects observed are the result of 
gene specific epigenetic results, rather than genome-wide 
effects.
Limitations associated with the use of both the biallelic 
and triallelic model of the 5-HTTLPR polymorphism exist 
as results differ depending on the model used. This calls into 
question the validity of the different models, and creates a 
need for further research on the nature of the S and L alleles 
related to this polymorphism so as to correctly identify 
which model is accurate, or if a different model is needed.
The studies that included an epigenetic component exam-
ine it through DNA obtained from blood, rather than from 
the brain (see Table 5), which call into question the accu-
racy to which the epigenetic results reflect central brain 
Table 5  Limitations of the studies included in the systematic review
Study Study limitations
Díaz-Marsá et al. [28] Sample 100% female
Small sample size (n = 100)
Small sample size of ED groups is too small to allow comparisons of platelet MAO reduction between ED subtypes
Steiger et al. [32] Sample 100% female
Small sample size (n = 308)
Small observed group differences in the mean methylation of the DRD2 promoter gene (~ 1%)
Measures of DNA methylation obtained through peripheral biomarkers
Lack of “neutral’ control gene
Many confounding variables were not assessed or controlled for
Steiger et al. [24] Sample 100% female
Small sample size (n = 59)
Discrepancies in findings when using the biallelic vs triallelic model of the 5-HTTLPR promoter gene
Measures of DNA methylation obtained through peripheral biomarkers
Steiger et al. [20] Sample 100% female
Small sample size (n = 92)
Discrepancies in findings when using the biallelic vs triallelic model of the 5-HTTLPR promoter gene
Measures of DNA methylation obtained through peripheral biomarkers
Steiger et al. [32] Sample 100% female
Small sample size (n = 96)
Measures of DNA methylation obtained through peripheral biomarkers
Lack of “neutral’ control gene
Treatment of medication use as a unitary effect, rather effect based on medication used
No control for the confounding effect medication use may have on analyses
Thaler et al. [33] Sample 100% female
Small sample size (n = 96)
Measures of DNA methylation obtained through peripheral biomarkers
Lack of “neutral’ control gene
Lack of control groups for the statistical analyses involving multiple comparisons
Vaz-Leal et al. [43] Sample 100% female
Small sample (n = 105) made comparisons between cortisol suppressors and cortisol non-suppressors impossible 
(non-suppressors in control group, n = 0; non-suppressors in ED group, n = 7)
Use of 24-h urine excretion as the source of data for neurotransmitter activity
Did not assess potential comorbid psychopathologies in the ED group
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processes. That said, it is often unethical to use more inva-
sive research methods, and there is increasing evidence that 
the use of peripheral biomarkers to assess psychopathologi-
cal disorders provides an acceptable proxy for neurobiologi-
cal processes, especially in relation to epigenetics [50]. As 
well, research has recognised a correspondence between 
brain-derived and blood-derived gene expression signals, 
indicating that epigenetic patterns observed through periph-
eral biomarkers are likely an acceptable indication for epige-
netic patterns occurring in the brain [32, 34, 50].
Finally, most studies (n = 3) used BN and BSD inter-
changeable. Although they do have different diagnostic 
criteria, evidence suggests that BSD does not significantly 
differ from BN on many clinical variables [3]. Therefore, 
this may be acceptable; however, the results are not specific 
to either BN or BSD.
Discussion
The present review identified and appraised seven studies 
relevant to BN/BSD, BPD, and a genetic/epigenetic compo-
nent. All the studies indicated differences between individu-
als with BN/BSD-BPD compared to those with BN/BSD, 
and HC. When interpreting the findings, it is important to 
keep in mind the small sample size and nature of the stud-
ies included in the review. The current research ultimately 
suggests that BN/BSD-BPD is likely a different condition 
from both BN/BSD and BPD; however, much more research 
is needed to confirm this and to clearly understand the aetiol-
ogy of the condition.
An evidence-based genetic/epigenetic aetiological model 
of BN/BSD-BPD will be proposed. It is hoped that this 
model will not only clearly illustrate the current understand-
ing of the genetics/epigenetics relevant to this psychopathol-
ogy, but will also demonstrate that BN/BSD-BPD is likely 
different from BN/BSD or BPD (as the current research 
findings suggest). Generally, the genetic/epigenetic aetio-
logical model of BN/BSD-BPD can be divided into three 
parts: genetics, epigenetics, and environmental pressures 
(childhood abuse), where the environmental pressures are 
largely correlated with the epigenetic effects (see Fig. 2). 
As the key findings of the papers included in this review 
have illustrated, individuals with BN/BSD-BPD seem to 
have genetic differences compared to individuals with BN/
BSD or HC as they generally display greater frequencies of 
the “low-functioning” S allele for the 5-HTTLPR gene poly-
morphism [20, 24] and largely show reduced MAO activity 
[28, 43]. These individuals also exhibit gene methylation 
patterns that are significantly different from individuals with 
BN/BSD and HC. These methylation differences include 
changes in methylation of the DRD2 gene, BDNF, and the 
NR3C1 gene. Further, current research suggests individuals 
with BN/BSD-BPD were more likely to have experienced 
Fig. 2  A genetic/epigenetic aetiological model of BN/BSD-BPD. The coloured boxes beside the symptom/behaviour indicate which genetic and/
or epigenetic variable(s) are correlated with it
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childhood abuse (physical and sexual) compared to their 
counterparts with BN/BSD or HC, and childhood abuse 
(physical and sexual) was frequently (but not always) associ-
ated with the methylation differences observed in this popu-
lation. Therefore, individuals with BN/BSD-BPD seem to 
differ from those with BN/BSD and HC on genetic, epige-
netic, and environmental levels, suggesting BN/BSD-BPD 
may be a unique condition. Decreased serotonin and MAO 
activity is seen in those with BN/BSD and BPD, however, 
to a lesser degree than seen in BN/BSD-BPD. Serotonin and 
MAO variation is an important genetic aspect of BN/BSD-
BPD, however, epigenetic changes, largely resulting from 
childhood abuse, seems to be the primary factor that sets 
BN/BSD-BPD apart from both BN/BSD and BPD as these 
epigenetic changes are observed to be significantly different 
when comparing individuals with BN/BSD-BPD to those 
with BN/BSD or BPD.
When interpreting the genetic/epigenetic aetiological 
model of BN/BSD-BPD it is important to understand the 
limitations of the model. Firstly, the model is most rel-
evant to women with BN/BSD-BPD as current literature 
about BN/BSD-BPD has been conducted exclusively on 
women. Secondly, only a couple of papers have been pub-
lished regarding each of the genetic/epigenetic aspects of 
this condition. Although the findings are convincing when 
considered alongside previous literature about the relevant 
genetics/epigenetics, BN/BSD, and independent BPD, 
more studies are needed to properly validate the findings. 
The same holds true for the studies about the epigenetic 
changes. As well, it is important to be aware that the present 
model almost certainly does not encompass all the genetic 
and epigenetic differences the BN/BSD-BPD population 
displays, due to a lack of research on this topic. Only a few 
studies have been conducted regarding the genetic/epigenetic 
aspect of BN/BSD-BPD as this condition is just becoming 
recognized and the research about genetics and epigenetics 
pertaining to mental health disorders is in its infancy. Fur-
thermore, genotype and DNA methylation also interact for 
many genes, resulting in potentially different effects arising 
due to epigenetic changes in some individuals compared to 
others [51], however, genotype-DNA methylation interac-
tions of the genes under question are not yet clearly under-
stood. Ultimately, the present genetic/epigenetic aetiological 
model of BN/BSD-BPD serves as a visual representative of 
the current findings and demonstrates the need for further 
research on this condition.
It is important to note that the genetic, epigenetic, and 
environmental factors discussed throughout the present 
review do not cause an individual to develop BN/BSD-
BPD, they simply interact, likely to increase the possibility 
that an individual may develop this condition. Furthermore, 
the ways in which these factors interact remains unclear. 
Recently, an interesting theory was proposed that suggests 
an individual with a genetic predisposition for a condition 
may unknowingly seek out environments that could trig-
ger an epigenetic change likely resulting in the emergence 
of the condition [52]. If this theory holds for the present 
condition, the genetic/epigenetic aetiological model of BN/
BSD-BDP presented above would become more complex 
and an arrow from the “genetics” box could be added that 
leads to the “environmental factors” box (childhood sexual 
and physical abuse), suggesting a more complex interaction 
between genetics, epigenetics, environmental factors, and 
psychopathy. Presently, no research has been conducted that 
specifically examines the genetic predispositions relevant to 
BN/BSD-BPD (i.e., decreased serotonin and MAO activity) 
and their influence on an individual’s environmental situ-
ations. Future studies that explore this would be of great 
interest and could be used to make the present genetic/epige-
netic aetiological model more complex. As well, these stud-
ies would also be beneficial as they would help to determine 
the degree to which these genetic and epigenetic changes are 
premorbid or if they are acute state changes associated with 
BN/BSD-BPD.
Conclusions
The present systematic review provided an exhaustive sum-
mary of the current literature on BN/BSD-BPD and the 
genetic/epigenetic variables associated with this psychopa-
thology. The results indicated that BN/BSD-BPD is signifi-
cantly different than BN/BSD and HC on many genetic and 
epigenetic variables, suggesting that it may be a unique con-
dition. As such, a preliminary genetic/epigenetic aetiologi-
cal model of this condition was proposed. This model out-
lines the genetic and epigenetic variables that are currently 
believed to influence specific symptoms and behaviours of 
BN/BSD-BPD, and illustrates the likely role of childhood 
abuse in these conditions.
It is important to acknowledge that the current research 
is very sparse, and more than anything the present review 
hopes to illustrate the need for further research regarding 
the genetic/epigenetic aspects of BN/BSD-BPD. Additional 
research is needed not only to validate the current findings, 
but also to more fully understand the genetic/epigenetic aeti-
ology of BN/BSD-BPD. Furthermore, mental health condi-
tions, including BN/BSD and BPD are often comorbid with 
other psychiatric disorders and research is needed to assess 
how relevant comorbidities affect the current findings.
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